Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI321 in Advanced Solid Tumors
NCT04911894Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI321 in solid tumor (advanced stage), sponsored by Innovent Biologics. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities at 28 days and Percentage of Participants with Adverse Events at 2 years. Started Jun 2021; status: completed.
02
Drugs
IBI321
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04911894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911894.